Adjuvant trastuzumab: Does time really matter?

Oncologist

Volumn 18, Issue 5, 2013, Pages 490-492

  Swain, Sandra M ^a,b  

^a WASHINGTON CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; HUMAN; NOTE; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; FEMALE; HUMANS; RECEPTOR, ERBB-2;

EID: 84878241618     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0094     Document Type: Note

References (24)

1. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182
2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-1672
3. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684
4. Slamon D, EiermannW,RobertNet al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-1283
5. Spielmann M, Roche ́ H, Delozier T et al. Trastuzumab for patients with axillary-node-positive breast cancer: Results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009;27:6129-6134
6. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-820
7. Joensuu H, Bono P, Kataja V et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer trial. J Clin Oncol 2009;27: 5685-5692
8. Protocol of Herceptin Adjuvant With Reduced Exposure, a Randomised Comparison of 6 Months versus 12 Months in all Women Receiving Adjuvant Herceptin. Available at http://clinicaltrials.gov/ct2/show/NCT00381901. Accessed February 27, 2013
9. Persephone: Duration of Trastuzumab With Chemotherapy in Women With Early Stage Breast Cancer: Six Months Versus Twelve. Available at http://clinicaltrials.gov/ct2/show/NCT00712140. Accessed February 27, 2013
10. A Multicenter Randomized Phase III Study Comparing 6 Versus 12 Months of Trastuzumab in Combination With Dose Dense Docetaxel Following FE75C as Adjuvant Treatment of Women With Axillary Lymph Node Positive Breast Cancer OverexpressingHER2. Available at http://clinicaltrials.gov/ct2/show/NCT00615602. Accessed February 27, 2013
11. ARandomized Phase III Study Comparing Trastuzumab Plus Docetaxel (HT) Followed by 5-FU, Epirubicin, and Cyclophosphamide (FEC) to the Same Regimen Followed by Single-Agent Trastuzumab as Adjuvant Treatments for Early Breast Cancer. Available at http://clinicaltrials.gov/ct2/show/NCT00593697. Accessed February 27, 2013
12. Short-HER: Multicentric Randomised Phase III Trial of 2 Different Adjuvant Chemotherapy Regimens Plus 3 Versus 12 Months of Trastuzumab in HER2 Positive Breast Cancer Patients. Available at http://clinicaltrials.gov/ct2/show/NCT00629278. Accessed February 27, 2013
13. Goldhirsch A, Piccart-Gebhart M, Procter M et al. HERA trial: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy inwomenwith HER2- positive early breast cancer at 8 years of median follow up. Cancer Res 2012(suppl 3);72:S5-S12
14. Pivot X, Romieu G, Bonnefoi H et al. PHARE trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. Cancer Res 2012(SUPPL.3);72:S5-S13
15. Romond EH, Jeong JH, Rastogi P et al. Sevenyear follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012;30:3792-3799
16. Perez EA, Suman VJ, Davidson NE et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 2011;29:4491-4497
17. Perez EA, Romond EH, Suman VJ et al. Fouryear follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011;29:3366-3373
18. Pegram M, Hsu S, Lewis G et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241-2251
19. ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D. Available at http://clinicaltrials.gov/ct2/show/NCT00490139. Accessed February 27, 2013
20. A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients With HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab With Chemotherapy Plus Trastuzumab Plus Bevacizumab. Available at http://clinicaltrials.gov/ct2/show/NCT00625898. Accessed February 27, 2013
21. A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer. Available at http://clinicaltrials.gov/show/NCT01358877. Accessed February 27, 2013
22. Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25-32
23. Rimawi MF, Mayer IA, Forero A et al. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol 2013 April 8 [Epub ahead of print].
24. Romond E, Suman VJ, Jeong J-H et al. Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. Cancer Res. 2012(SUPPL.3);72:S5.